Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies (opens in new window) for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Manage cookies
Accept & continue
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
myFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
    Most Read
    • Why the second wave of Covid-19 appears to be less lethal
    • Government threatens to take direct control of Transport for London
    • Boris Johnson forced to ditch public spending master plan
    • UK and EU to resume talks in final push for post-Brexit trade deal
    • EU carmakers call on Brussels to ‘reconsider’ Brexit stance
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    • US Presidential Election 2020
    Most Read
    • Apollo investor halts new commitments over Leon Black’s Jeffrey Epstein ties
    • Tesla’s move into mining aimed at energising battery supply chain
    • Two top Morgan Stanley commodities traders lose jobs over use of WhatsApp
    • Dollar weakens as investors keep attention on US stimulus talks
    • US Republicans must make peace with the state
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Apollo investor halts new commitments over Leon Black’s Jeffrey Epstein ties
    • Tesla’s move into mining aimed at energising battery supply chain
    • Two top Morgan Stanley commodities traders lose jobs over use of WhatsApp
    • Ikea seeks to disrupt itself before it is disrupted
    • Apollo to review Leon Black’s relationship with Jeffrey Epstein
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • Investors opt for the ‘do nothing’ trade ahead of US election
    • MMT: The case against Modern Monetary Theory
    • A brutal crackdown in Nigeria exposes weakness at the top
    • EU enjoys ‘outrageous demand’ for first Covid-related bond
    • European corporates signal earnings have bottomed out
  • Graphics
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Instant Insight
    • Lex
    • Alphaville
    • Obituaries
    • Letters
    Most Read
    • Ikea seeks to disrupt itself before it is disrupted
    • US Republicans must make peace with the state
    • The threat of long economic Covid looms
    • ‘Bank of Son and Daughter’ could pay dearly for retirement
    • The good, bad and ugly of soaring tech stocks
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • What I wish I’d known at the start of the pandemic
    • I expect to be made redundant. How do I prepare?
    • Good riddance to a lot of what I thought was normal life
    • Offices have a future — but what about other workplaces? | Free to Read
    • Consultants’ change fetish is clichéd and confused
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Borat returns with Giuliani, Pence and a female accomplice
    • ‘Bank of Son and Daughter’ could pay dearly for retirement
    • Wish I were there: the glory of California’s redwoods
    • It’s the great wall of Tesla 
    • Rome’s most charming small hotels: FT readers’ top tips
  • How to Spend It
  • Sign In
  • Subscribe
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Graphics
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
  • Sign In
  • Subscribe

Hannah Kuchler

US pharma and biotech correspondent
Hannah Kuchler reports on pharma, biotech and healthcare. After covering Silicon Valley for over five years, she's now focusing on how technology is transforming our health.
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Thursday, 22 October, 2020
    FT SeriesCoronavirus: Could the world have been spared?
    How New York’s mis-steps let Covid-19 overwhelm the US

    City leaders saw the threat but did not act: why arguments and rivalries among politicians and power groups allowed disaster to unfold

  • Wednesday, 21 October, 2020
    US opioid epidemic
    Opioid maker Purdue Pharma agrees $8bn US settlement

    Members of billionaire Sackler family to pay $225m in related civil settlement

  • Friday, 16 October, 2020
    InterviewLunch with the FT
    Atul Gawande: ‘It’s not just about keeping people safe’

    The surgeon and ‘Being Mortal’ author on fixing US healthcare — and the battle to beat Covid-19

  • Wednesday, 7 October, 2020
    Coronavirus treatment
    Lilly seeks emergency approval for Covid drug

    Antibody would be one of first treatment options for patients with mild or moderate illness

  • Monday, 5 October, 2020
    Bristol-Myers Squibb Co
    Bristol-Myers Squibb to buy heart treatment maker for $13.1bn

    MyoKardia deal is US company’s first major acquisition since Celgene last year

  • Saturday, 3 October, 2020
    Donald Trump
    Trump is moved to military hospital in Maryland

    President given experimental treatments for Covid-19 at Walter Reed facility

  • Friday, 2 October, 2020
    AnalysisThe Big Read
    With 1m dead, are we any better at treating Covid-19?

    The survival rate for people suffering from coronavirus has improved but doctors still want more effective therapies

  • Thursday, 1 October, 2020
    Coronavirus treatment
    Pfizer chief hits out at politicisation of Covid-19 vaccine

    Albert Bourla says discussion of timeline during presidential debate had confused public

  • Wednesday, 30 September, 2020
    Coronavirus treatment
    Moderna chief says its vaccine won’t be ready before US election

    Cautious timeline deals blow to Trump’s hope of authorising immunisation by start of November

  • Promoted Content
  • Tuesday, 29 September, 2020
    Coronavirus treatment
    FDA chief stands by vaccine approval criteria despite Trump pressure

    Guidelines agreed with pharmaceuticals companies make pre-election jab unlikely

  • Friday, 25 September, 2020
    Coronavirus pandemic
    Study suggests few Americans have Covid-19 antibodies

    Survey of dialysis patients indicates majority may not have an immune response despite high infection numbers

  • Wednesday, 23 September, 2020
    Coronavirus treatment
    J&J launches first phase 3 trial of single-dose vaccine

    World’s largest healthcare company hopes to catch rivals working on two-jab products

  • Wednesday, 23 September, 2020
    Coronavirus treatment
    US regulators set higher bar for Covid-19 vaccine

    Stricter FDA guidelines make it unlikely one will be approved before November election

  • Tuesday, 22 September, 2020
    Coronavirus treatment
    Scientists call for clarity on AstraZeneca’s Covid vaccine trial

    Experts fear damage to public trust as tests remain on hold in US but restart elsewhere

  • Monday, 21 September, 2020
    Biotech
    Illumina agrees $8bn deal for cancer screening group Grail

    Genetic sequencing company set to take full ownership of start-up

  • Thursday, 17 September, 2020
    Coronavirus treatment
    Moderna signals slower timeline for Covid-19 vaccine

    Data analysis may have to wait until December despite Trump push for pre-election approval

  • Saturday, 12 September, 2020
    Gilead Sciences Inc
    Gilead nears deal to buy cancer drug maker for $20bn

    Offer is worth close to double New Jersey-based Immunomedics’ market value

  • Friday, 11 September, 2020
    AnalysisCoronavirus pandemic
    Covid vaccine becomes divisive issue in US election campaign

    Donald Trump, a long-term sceptic, is pushing for a speedy approval while Democrats urge caution

  • Wednesday, 9 September, 2020
    Coronavirus treatment
    AstraZeneca puts vaccine trial on hold after participant falls ill

    Trial could resume early next week after review of suspected adverse reaction

  • Tuesday, 8 September, 2020
    ReviewNon-Fiction
    Anti-vaxxers: How to Challenge a Misinformed Movement

    Jonathan Berman’s book is a guide to strategies for converting the ‘vaccine hesitant’

  • Tuesday, 8 September, 2020
    FT News Briefing podcast10 min listen
    Six months in: a look at how coronavirus changed the west

    The FT’s Gillian Tett and Hannah Kuchler look at how Covid-19 changed the world in six months

  • Monday, 7 September, 2020
    Coronavirus treatment
    Trump and Biden accuse each other of politicising Covid-19 vaccine

    Presidential campaigns spar over push to speed up approval for a potential jab

  • Thursday, 3 September, 2020
    Coronavirus treatment
    Pfizer boss warns on risk of fast-tracking vaccines

    Comments come as US appears to be preparing to distribute a vaccine ahead of November presidential election

  • Wednesday, 2 September, 2020
    Coronavirus treatment
    Top US health official prepares for pre-election vaccine

    Director of CDC asks state governors to speed up opening of distribution centres

  • Sunday, 30 August, 2020
    Airlines
    United Airlines scraps change fees for domestic tickets

    Chicago-based carrier tries to lure passengers back to the skies by ending unpopular $200 charges

Previous You are on page 1 Next

Useful links

Support

View Site TipsHelp CentreAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

FT LiveShare News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingContracts & Tenders
Executive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubMBA Rankings
Enterprise ToolsNews feedNewslettersCurrency Converter
More from the FT Group
Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2020. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
    • US Presidential Election 2020
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Graphics
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Instant Insight
    • Lex
    • Alphaville
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In